LL-37: Double-Edged Sword in Autoimmune Disease and Viral Infections

LL-37 serves dual roles — protecting against infections but also triggering autoimmune inflammation in psoriasis and lupus by acting as an autoantigen that activates interferon-producing immune cells.

Pahar, Bapi et al.·Vaccines·2020·Moderate EvidenceReview
RPEP-05047ReviewModerate Evidence2020RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not applicable (narrative review)
Participants
Not applicable (narrative review)

What This Study Found

LL-37 complexed to self-DNA acts as an autoantigen in psoriasis and lupus, activating interferon production by plasmacytoid dendritic cells, while also having dual antiviral and pro-inflammatory roles.

Key Numbers

LL-37 produced by neutrophils, monocytes, macrophages, epithelial cells; acts as autoantigen when complexed with self-DNA

How They Did This

Narrative review of LL-37 immunomodulatory roles in autoimmune diseases (psoriasis, lupus) and viral infections.

Why This Research Matters

LL-37 is central to both antimicrobial defense and autoimmune disease. Understanding its dual roles is essential for developing therapies that preserve its protective functions while blocking its pathogenic activities.

The Bigger Picture

LL-37 exemplifies the fine line between immune defense and autoimmunity — the same peptide that protects against infections can drive chronic inflammatory disease when regulation fails.

What This Study Doesn't Tell Us

Review without new experimental data; LL-37 roles in different viral infections vary widely; therapeutic targeting strategies are largely conceptual.

Questions This Raises

  • ?Can LL-37-DNA complex formation be blocked specifically to treat psoriasis without compromising antimicrobial defense?
  • ?Which viral infections benefit most from LL-37 antiviral activity versus being worsened by its inflammatory effects?
  • ?Could LL-37 inhibitors prevent autoimmune flares triggered by skin injury?

Trust & Context

Key Stat:
Autoantigen in psoriasis and lupus LL-37 complexed to self-DNA triggers plasmacytoid dendritic cell interferon production driving autoimmune inflammation
Evidence Grade:
Well-established mechanisms reviewed from published literature, but therapeutic targeting strategies remain largely theoretical.
Study Age:
Published in 2020; LL-37 gained additional attention during COVID-19 research for its potential antiviral and immunomodulatory roles.
Original Title:
Immunomodulatory Role of the Antimicrobial LL-37 Peptide in Autoimmune Diseases and Viral Infections.
Published In:
Vaccines, 8(3) (2020)
Database ID:
RPEP-05047

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

Can your own antimicrobial peptides cause disease?

Yes — LL-37 normally fights infections, but when it binds to self-DNA fragments it can trigger autoimmune inflammation in psoriasis and lupus by activating interferon-producing immune cells.

Does LL-37 help fight viruses?

LL-37 has antiviral activity against several viruses, but it can also worsen inflammation in viral infections — making its role context-dependent and sometimes counterproductive.

Read More on RethinkPeptides

Cite This Study

RPEP-05047·https://rethinkpeptides.com/research/RPEP-05047

APA

Pahar, Bapi; Madonna, Stefania; Das, Arpita; Albanesi, Cristina; Girolomoni, Giampiero. (2020). Immunomodulatory Role of the Antimicrobial LL-37 Peptide in Autoimmune Diseases and Viral Infections.. Vaccines, 8(3). https://doi.org/10.3390/vaccines8030517

MLA

Pahar, Bapi, et al. "Immunomodulatory Role of the Antimicrobial LL-37 Peptide in Autoimmune Diseases and Viral Infections.." Vaccines, 2020. https://doi.org/10.3390/vaccines8030517

RethinkPeptides

RethinkPeptides Research Database. "Immunomodulatory Role of the Antimicrobial LL-37 Peptide in ..." RPEP-05047. Retrieved from https://rethinkpeptides.com/research/pahar-2020-immunomodulatory-role-of-the

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.